Sean Bell is head of new ventures at Spring Health, a very well-funded mental health company. They’ve built a tech platform that its providers (both contractors and FT employees) are on, and spend a lot of time using machine learning to match patients to therapists, to augment the care and also measure the impact of…
Philips is showcasing its partnerships and new products at RSNA 2024, including an expanded collaboration with AWS and a CT scanner that the company said uses up to 80% less radiation than traditional systems. The post 3 Innovations Philips Is Showcasing at RSNA 2024 appeared first on MedCity News.
Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing. The post Novartis Tries Again in Huntington’s, Putting Up…
Meng Li (2024) has a nice summary of the generalized cost effectiveness analysis (GCEA) user guide paper (see Shafrin et al. 2024) that was published last month. The GCEA methodology encompasses 15 ‘petals’ across four domains. The uncertainty domain captures how risk aversion and uncertainty in treatment outcomes impact value, including aspects such as outcome…
In a recent report, Define Ventures revealed key insights from payers and providers on how they’re shaping their AI strategies. The post 4 Key Insights into Payer and Provider Leaders’ Vision for AI appeared first on MedCity News.
At RSNA24, Eric Topol, M.D., gave his audience a glimpse into the future of medicine
The FDA cited deficiencies in its govorestat’s application in galactosemia, a rare metabolic disease, Applied Therapeutics said. The biotech is still on track to submit a separate application for the drug in sorbitol dehydrogenase (SORD) deficiency, another rare disease that has no FDA-approved therapies. The post Applied Therapeutics Drug Is Denied FDA Approval in Rare…
Harbor Health says its ultimate mission is to redesign the health system so that doctors and the team working with them truly get to know the people in their care
This page tracks recent state actions to extend Medicaid postpartum coverage, including approved and pending 1115 waivers, legislation that will require the state to seek federal approval through a SPA or 1115 waiver, submitted and approved SPAs, and coverage financed solely with state funds.
Besides the impact to physician satisfaction, the cost of this administrative burden is staggering: Organizations spend $82.7 billion annually on documentation, coding, and other administrative tasks, straining both budgets and staff. The post Tackling Burnout: How AI Lifts the Coding Burden on Physicians appeared first on MedCity News.